[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FR3083085B1 - Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide - Google Patents

Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide Download PDF

Info

Publication number
FR3083085B1
FR3083085B1 FR1855943A FR1855943A FR3083085B1 FR 3083085 B1 FR3083085 B1 FR 3083085B1 FR 1855943 A FR1855943 A FR 1855943A FR 1855943 A FR1855943 A FR 1855943A FR 3083085 B1 FR3083085 B1 FR 3083085B1
Authority
FR
France
Prior art keywords
amyline
aqueous solution
analogue
receptor agonist
polyaminoacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1855943A
Other languages
English (en)
Other versions
FR3083085A1 (fr
Inventor
You-Ping Chan
Alexandre Geissler
Romain Noel
Richard Charvet
Nicolas Laurent
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1855943A priority Critical patent/FR3083085B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to US16/213,865 priority patent/US11129877B2/en
Priority to AU2018380901A priority patent/AU2018380901A1/en
Priority to EA202091201A priority patent/EA202091201A1/ru
Priority to PCT/EP2018/083943 priority patent/WO2019110788A1/fr
Priority to SG11202005319PA priority patent/SG11202005319PA/en
Priority to JP2020531134A priority patent/JP2021505616A/ja
Priority to EP18815677.2A priority patent/EP3740227A1/fr
Priority to KR1020207019242A priority patent/KR20200106890A/ko
Priority to CN201880088465.3A priority patent/CN111683674A/zh
Priority to CA3084699A priority patent/CA3084699A1/fr
Priority to BR112020011479-0A priority patent/BR112020011479A2/pt
Priority to MX2020005916A priority patent/MX2020005916A/es
Priority to IL275146A priority patent/IL275146B1/en
Priority to MA051600A priority patent/MA51600A/fr
Publication of FR3083085A1 publication Critical patent/FR3083085A1/fr
Priority to PH12020550804A priority patent/PH12020550804A1/en
Priority to SA520412138A priority patent/SA520412138B1/ar
Publication of FR3083085B1 publication Critical patent/FR3083085B1/fr
Application granted granted Critical
Priority to US17/404,735 priority patent/US20210401943A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une composition sous forme d'une solution aqueuse injectable, dont le pH est compris entre 6,0 et 8,0, comprenant au moins : a) de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline ; b) un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes Hy, ledit co-polyaminoacide étant constitué d'unités glutamiques ou aspartiques et lesdits radicaux hydrophobes Hy étant de formule X suivante : c) caractérisée en ce que la composition ne comprend pas d'une insuline basale dont le point isoélectrique pI est compris entre 5,8 et 8,5. Elle concerne également une composition caractérisée en ce qu'elle comprend en outre une insuline prandiale.
FR1855943A 2017-12-07 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide Active FR3083085B1 (fr)

Priority Applications (18)

Application Number Priority Date Filing Date Title
FR1855943A FR3083085B1 (fr) 2018-06-29 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020005916A MX2020005916A (es) 2017-12-07 2018-12-07 Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
AU2018380901A AU2018380901A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
PCT/EP2018/083943 WO2019110788A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SG11202005319PA SG11202005319PA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
JP2020531134A JP2021505616A (ja) 2017-12-07 2018-12-07 アミリン、アミリンアゴニスト受容体またはアミリン類似体およびコポリアミノ酸を含む注射水溶液の形態の組成物
EP18815677.2A EP3740227A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
KR1020207019242A KR20200106890A (ko) 2017-12-07 2018-12-07 아밀린, 아밀린 작용제 수용체 또는 아밀린 유사체 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
IL275146A IL275146B1 (en) 2017-12-07 2018-12-07 Preparations in the form of an aqueous solution for injection that include amylin, an amylin receptor agonist or an amylin analog and copolyamino acid
CA3084699A CA3084699A1 (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US16/213,865 US11129877B2 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid
EA202091201A EA202091201A1 (ru) 2018-06-29 2018-12-07 Композиции в форме инъецируемого водного раствора, содержащие амилин, агонист рецептора амилина или аналог амилина и сополиаминокислоту
CN201880088465.3A CN111683674A (zh) 2017-12-07 2018-12-07 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
MA051600A MA51600A (fr) 2017-12-07 2018-12-07 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
BR112020011479-0A BR112020011479A2 (pt) 2017-12-07 2018-12-07 composições na forma de uma solução aquosa injetável caracterizada pelo fato de que compreende amilina, um agonista do receptor de amilina ou um análogo de amilina e um co-poliaminoácido
PH12020550804A PH12020550804A1 (en) 2017-12-07 2020-06-04 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
SA520412138A SA520412138B1 (ar) 2017-12-07 2020-06-07 تركيبات في صورة محلول مائي قابل للحقن يشتمل على أميلين، ومستقبل مساعد أميلين أو نظير أميلين وحمض بولي أمينو مشترك
US17/404,735 US20210401943A1 (en) 2017-12-07 2021-08-17 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analogue and a co-polyamino acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1855943A FR3083085B1 (fr) 2018-06-29 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR1855943 2018-06-29

Publications (2)

Publication Number Publication Date
FR3083085A1 FR3083085A1 (fr) 2020-01-03
FR3083085B1 true FR3083085B1 (fr) 2020-10-02

Family

ID=65031316

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1855943A Active FR3083085B1 (fr) 2017-12-07 2018-06-29 Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Country Status (2)

Country Link
EA (1) EA202091201A1 (fr)
FR (1) FR3083085B1 (fr)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
BR9407424A (pt) 1993-09-07 1996-04-09 Amylin Pharmaceuticals Inc Métodos para regular motilidade gastrointestinal
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2855521B1 (fr) * 2003-05-28 2005-08-05 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement h ydrophobe et leurs applications notamment therapeutiques.
EP2241327A1 (fr) 2006-03-15 2010-10-20 Novo Nordisk A/S Melange d'amyline et d'insuline
WO2009004627A2 (fr) 2007-07-02 2009-01-08 Medingo Ltd. Dispositif pour l'administration de médicaments
MX349383B (es) 2011-10-31 2017-07-26 Xeris Pharmaceuticals Inc Formulaciones para el tratamiento de diabetes.
CN104114155B (zh) * 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液

Also Published As

Publication number Publication date
EA202091201A1 (ru) 2020-09-29
FR3083085A1 (fr) 2020-01-03

Similar Documents

Publication Publication Date Title
FR3001895B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
FR3001896B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
WO2019110797A8 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
SA518400588B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7يشتمل على أنسولين قاعدي واحد على (pi)الأقل تتراوح نقطة التعادل الكهربائي الخاصة به من5.8إلى8.5وحمض بولي أميني مشترك يحمل شحنات كربوكسيلات وجذور كارهة للماء
SA520412141B1 (ar) محلول قابل للحقن عند الرقم الهيدروجيني 7 يشتمل على إنسولين قاعدي واحد على الأقل يتراوح الخاص به بين 5.8 و8.5 وحمض بولي أمينو مشترك حامل لشحنات pi كربوكسيلات وشقوق غير قابلة للذوبان في الماء
PH12020550804A1 (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
BRPI0606142A2 (pt) agonistas de pyy e usos dos mesmos
MA49678A (fr) Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
CY1112353T1 (el) Παραγωγα μεταστινης και χρηση αυτων
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
EA200800233A1 (ru) Композиция иммуноконьюгата
SG11201810939PA (en) Compositions in the form of an injectable aqueous solution, comprising human glucagon and an end-grafted copolyamino acid
BRPI0810715A2 (pt) composições macromoleculares de alta viscosidade para tratamento de condições oculares
PE20100035A1 (es) Proteina de cereal hidrolizado parcialmente
RU2016136530A (ru) Композиции селеноорганических соединений и способы их применения
GEP20207139B (en) Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
BR112013006087A2 (pt) lubrificantes de transportador incluindo emulsões e métodos para empregá-los
DE602004012289D1 (de) Bioaktive peptide, die durch enzymatische hydrolyse aus den proteinen von eiweiss gewonnen werden
FR3061023B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074682B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MA39386A1 (fr) Utilisation d'une composition bitumineuse comme liant de collage
FR3031039B1 (fr) Composition apaisante pour animaux comprenant au moins un acide gras et de la nepetalactone
FR3074680B1 (fr) Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3051168B1 (fr) Lame d'essuyage pour balai d'essuie-glace

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200103

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

GC Lien (pledge) constituted

Effective date: 20210525

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

RG Lien (pledge) cancelled

Effective date: 20231011

PLFP Fee payment

Year of fee payment: 7